ライフサイエンスコーパス: be deemed to be

1 The recommended phase 2 dose was deemed to be 1.8 mg/kg of brentuximab vedotin and 90

2 These side effects are deemed to be a consequence of nonselective blockade

3 Populus euphratica has been deemed to be a promising candidate for stress respo

4 nical feasibility profile for this technique was deemed to be (a) a safety and feasibility profile si

5 and the level of local and global risk that is deemed to be acceptable.

6 The reliability of the SPLINTS system was deemed to be adequate for assessing scrub practition

7 The invasion was deemed to be almost eradicated in 2004 but our analy

8 The presence of specific copies has been deemed to be an essentially homoplasy-free phylogen

9 The 12B9m Ab was deemed to be an appropriate candidate for use as a p

10 A total of 1550 patients (23.2%) were deemed to be at high clinical risk and low genomic

11 , had gradable photographs in both eyes, and were deemed to be at risk of developing nuclear cataract

12 oracic and nonthoracic MRI examinations that were deemed to be clinically necessary.

13 776 exacerbations were deemed to be clinically significant.

14 or LVD, if the severity of coronary disease is deemed to be complex (SYNTAX >22) due to lower cardia

15 ic cultures were enrolled, and 1,703 (71.5%) were deemed to be compliant and acceptable for analysis.

16 ch the justification rules provided by RENEX were deemed to be correct by the expert.

17 (0.4% of total) described 8 innovations that were deemed to be decrementally cost-effective.

18 ead at the time of the follow-up survey, one was deemed to be due to rabies after a probable rabies e

19 polysaccharide product synthesized in vitro was deemed to be HA by enzymatic analyses; specific HA l

20 differences in the treatment of patients who were deemed to be "ideal candidates" for particular trea

21 with an IMiD-14 score higher than the cutoff was deemed to be IMiD-resistant.

22 -care immunosuppression, including those who are deemed to be immunologically quiescent on the basis

23 thylbutyl acetate, ethyl hexanoate and 3-MHA were deemed to be important, in accord with other studie

24 The use of ADT was deemed to be inappropriate as primary therapy for me

25 ed in the blood chemistry and CBC parameters were deemed to be incidental findings unrelated to the a

26 Cementum formation is deemed to be instrumental for the successful regenera

27 rature, and here named coadaptational drive, is deemed to be largely responsible for both increases i

28 Although carotid bruits are deemed to be markers of generalised atherosclerosis,

29 ts did not lead to a diagnosis of COPD, they were deemed to be missed opportunities.

30 tive of trisomy 21; the remaining 57 samples were deemed to be normal.

31 Most studies were deemed to be of poor quality and were excluded.

32 viduals who possessed a renal transplant and were deemed to be on a maximum safe dose of statin agent

33 the leech genes Lox7, Lox6, Lox20, and Lox5 are deemed to be orthologs of the Drosophila genes lab,

34 Mutations that were deemed to be pathogenic or probably pathogenic were

35 s of randomisation; only one of these deaths was deemed to be possibly chemotherapy related.

36 adverse events (primarily neutropenia) that were deemed to be possibly related to a study drug.

37 Eight grade 3 adverse events that were deemed to be possibly related to the study drug wer

38 containing ephedra alkaloids, and 31 percent were deemed to be possibly related.

39 tients receiving TNF inhibitors, of which 27 were deemed to be possibly, probably, or definitely rela

40 earch identified 3486 articles; 208 of these were deemed to be potentially eligible and were retrieve

41 to reduce the number of outpatient TTEs that were deemed to be rarely appropriate by published approp

42 Such approaches were deemed to be reasonable treatment for WM patients i

43 None of the grade 3-4 adverse events were deemed to be related to ODM-201.

44 Two on-treatment deaths during the study were deemed to be related to study drug by the investiga

45 of 154 such events in the moxifloxacin group were deemed to be related to study drug.

46 n the gemcitabine and cisplatin group; these were deemed to be related to study drugs in 15 (3%) and

47 patients (15.7%) but breaks in only 6 (3.2%) were deemed to be related to the sclerotomies.

48 e events; eight of these (in seven patients) were deemed to be related to the study device or surgery

49 m and four in the placebo arm, none of which were deemed to be related to the study drug.

50 umab, n=4 [0.3%]; placebo, n=2 [0.3%]); none were deemed to be related to the study product.

51 biotics clindamycin or cefoxitin, the sample is deemed to be resistant to these antibiotics, respecti

52 U.S. Atlantic Ocean south of Chesapeake Bay were deemed to be severely overfished and the food webs

53 Gas-phase clusters are deemed to be sigma-aromatic when they satisfy the 4n

54 cruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were rando

55 he metabolic evidence, when fully evaluated, is deemed to be suggestive, then the question of whether

56 Although P-MLVs are deemed to be the proximal agents of disease inductio

57 unknown DNA adducts, mass spectrometry (MS) is deemed to be the most promising technique.

58 were women in their 50s or 60s for whom EPD was deemed to be the best diagnosis, after infection, im

59 ct formation and that of s- and syn-products was deemed to be the consequence of a rapid equilibrium

60 layer surrounding the PSM because that layer was deemed to be the main factor determining the uptake

61 um tolerated dose was not reached, and 20 mg was deemed to be the recommended dose.

62 o sepsis and megacolon) in the placebo group was deemed to be treatment related.

63 Only one death was deemed to be treatment-related: one patient in the F

64 died during the study; none of these deaths were deemed to be treatment related by the investigator.

65 dnisone plus custirsen group, seven of which were deemed to be treatment related, versus 17 in the ca

66 zitaxel and prednisone group, eight of which were deemed to be treatment related.

67 No adverse events were deemed to be treatment related.

68 ported serious adverse events, none of which were deemed to be treatment related.

69 No adverse events in the linsitinib group were deemed to be treatment related; one death (due to s

70 Alerts that did not meet this standard were deemed to be unverified.

71 Attacks were deemed to be verified if they were reported by a mi

72 pends on whether their greater effectiveness is deemed to be worth their additional cost.